Publications by authors named "Y Stienstra"
A considerable number of patients present to hospitals in Eswatini each year following bites by venomous snakes. Effectively diagnosing and treating patients with snakebite envenoming requires healthcare workers to have a variety of generic and snakebite-specific medical skills. In several countries, however, healthcare workers have been found to have limited skills in managing snakebite patients.
View Article and Find Full Text PDFBackground: There is a dearth of information concerning the epidemiology of human scabies in prisons. Therefore, we aimed to assess the burden of scabies and ascertain if prevalence was high enough to warrant mass drug administration (MDA) with ivermectin in a medium security prison in central Ghana.
Methods: We conducted a cross-sectional study in December 2022 and recruited inmates at the Kumasi central prison in Ghana.
Venom-induced consumption coagulopathy (VICC) is a common complication of snakebite that is associated with hypofibrinogenemia, bleeding, disability, and death. In remote tropical settings, where most snakebites occur, the 20-minute whole blood clotting test is used to diagnose VICC. Point-of-care (POC) coagulation devices could provide an accessible means of detecting VICC that is better standardized, quantifiable, and more accurate.
View Article and Find Full Text PDFArticle Synopsis
- Clarithromycin extended-release (CLA-ER) was tested alongside rifampicin (RIF) for treating Mycobacterium ulcerans in a WHO drug trial, but RIF can lower CLA serum levels due to its effect on metabolism.
- The study involved 30 participants who provided dried blood samples over ten hours, with findings showing a non-significant decrease in CLA levels and a slight increase in systemic exposure compared to previous standard dosages.
- Ultimately, CLA co-administration didn't impact RIF levels or effectiveness, leading to unclear benefits of CLA-ER over immediate release formulations.
Background: Tuberculosis (TB), and especially its drug resistant forms, is responsible for not only significant mortality, but also considerable morbidity, still under-quantified. This study used four Patient-Reported Outcome Measures (PROMS) to assess the status of persons affected by drug-susceptible and drug-resistant TB during their TB treatment or after treatment completion, in Romania, the highest TB burden country in the EU.
Methods: People affected by TB in two different regions in Romania were included during and after treatment, following a cross-sectional design.